Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Nanomolecular targeting of dendritic cells for ovarian cancer therapy.

Cubillos-Ruiz JR, Fiering S, Conejo-Garcia JR.

Future Oncol. 2009 Oct;5(8):1189-92. doi: 10.2217/fon.09.101. Review. No abstract available.

2.

Nanooncology in ovarian cancer treatment.

Kasprzak B, Miskiel S, Markowska J.

Eur J Gynaecol Oncol. 2016;37(2):161-3. Review.

PMID:
27172737
3.

Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax.

Roby KF, Niu F, Rajewski RA, Decedue C, Subramaniam B, Terranova PF.

Adv Exp Med Biol. 2008;622:169-81. Review. No abstract available.

PMID:
18546627
4.

Targeting dendritic cell metabolism in cancer.

Zitvogel L, Kroemer G.

Nat Med. 2010 Aug;16(8):858-9. doi: 10.1038/nm0810-858. No abstract available.

PMID:
20689548
5.

Promising approaches in using magnetic nanoparticles in oncology.

Mikhaylov G, Vasiljeva O.

Biol Chem. 2011 Nov;392(11):955-60. doi: 10.1515/BC.2011.185. Review.

PMID:
21848508
6.

Biodegradable, polymeric nanoparticle delivery systems for cancer therapy.

Pridgen EM, Langer R, Farokhzad OC.

Nanomedicine (Lond). 2007 Oct;2(5):669-80. Review.

PMID:
17976029
7.

[Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].

Chen JN, Shen Q, Li SS.

Yao Xue Xue Bao. 2009 Apr;44(4):333-7. Review. Chinese.

PMID:
19545047
8.

Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy.

Sawicki JA, Anderson DG, Langer R.

Adv Exp Med Biol. 2008;622:209-19. doi: 10.1007/978-0-387-68969-2_17. Review.

PMID:
18546630
9.

Nanoparticles for tumor targeted therapies and their pharmacokinetics.

Wang J, Sui M, Fan W.

Curr Drug Metab. 2010 Feb;11(2):129-41. Review.

PMID:
20359289
10.

Engineered multifunctional nanocarriers for cancer diagnosis and therapeutics.

Shi D, Bedford NM, Cho HS.

Small. 2011 Sep 19;7(18):2549-67. doi: 10.1002/smll.201100436. Epub 2011 Jun 7. Review.

PMID:
21648074
11.

Targeting signaling pathways in ovarian cancer.

Reibenwein J, Krainer M.

Expert Opin Ther Targets. 2008 Mar;12(3):353-65. doi: 10.1517/14728222.12.3.353. Review.

PMID:
18269344
12.

Targeting of nanoparticles in cancer: drug delivery and diagnostics.

Talekar M, Kendall J, Denny W, Garg S.

Anticancer Drugs. 2011 Nov;22(10):949-62. doi: 10.1097/CAD.0b013e32834a4554. Review.

PMID:
21970851
13.

Surface-active liposomes for targeted cancer therapy.

Sofou S.

Nanomedicine (Lond). 2007 Oct;2(5):711-24. Review.

PMID:
17976032
14.

New Strategies in Cancer Nanomedicine.

Tong R, Kohane DS.

Annu Rev Pharmacol Toxicol. 2016;56:41-57. doi: 10.1146/annurev-pharmtox-010715-103456. Epub 2015 Oct 28. Review.

PMID:
26514197
15.

Tissue targeting in cancer: eIF4E's tale.

Borden KL.

Clin Cancer Res. 2009 Jul 1;15(13):4254-5. doi: 10.1158/1078-0432.CCR-09-0552. Epub 2009 Jun 9.

16.

Targeting multiplicity: the key factor for anti-cancer nanoparticles.

Gary-Bobo M, Vaillant O, Maynadier M, Basile I, Gallud A, El Cheikh K, Bouffard E, Morère A, Rébillard X, Puche P, Nirdé P, Garcia M.

Curr Med Chem. 2013;20(15):1946-55. Review.

PMID:
23409718
17.

Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma.

Tomasina J, Poulain L, Abeilard E, Giffard F, Brotin E, Carduner L, Carreiras F, Gauduchon P, Rault S, Malzert-Fréon A.

Int J Pharm. 2013 Dec 15;458(1):197-207. doi: 10.1016/j.ijpharm.2013.09.025. Epub 2013 Sep 29.

PMID:
24084450
18.

Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004.

Sood AK, Coleman RL, Wolf JK, Gershenson DM.

Expert Opin Pharmacother. 2005 Jun;6(7):1269-75. No abstract available.

PMID:
15957979
19.

Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review.

Ye H, Karim AA, Loh XJ.

Mater Sci Eng C Mater Biol Appl. 2014 Dec;45:609-19. doi: 10.1016/j.msec.2014.06.002. Epub 2014 Jun 20. Review.

PMID:
25491871
20.

Nanomedicines Targeting the Tumor Microenvironment.

Tong R, Langer R.

Cancer J. 2015 Jul-Aug;21(4):314-21. doi: 10.1097/PPO.0000000000000123. Review.

PMID:
26222084

Supplemental Content

Support Center